Consider appropriate patient types. Scarlette R., 17 years old. Student living with SMA. Scarlette hasn't received ITVISMA. Individuals shown were compensated for their time.

Jake

History:
Age: 9 years old¹
Treatment duration: 5 years, 11 months (following 2 years of supportive care)
Current SMA treatment: nusinersen—previously discussed transition to risdiplam, but his family decided to continue with nusinersen as it better aligns with their daily routine and lifestyle¹

Milestones¹:
Sit without support: YES
Stand without assistance: YES
Walk without assistance: NO

Current status:
Jake is currently able to stand and walk down the hallways at school, but his parents are worried about the potential for those abilities to decline over the remainder of his childhood years.

Considerations:
Jake’s parents want to help him maintain the motor function and mobility for which he’s fought so hard. They're eager to explore every option, especially one that can stop progression and offers a one-time dosing schedule that does not disrupt his academic and social schedule.

This hypothetical patient profile is based on patient experiences seen in clinical practice. This patient profile should not be used as a substitute for independent medical judgment. Models are for illustrative purposes and not actual patients. Individual results may vary.